Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years
Authors:
- Alexander KappAKAlexander Kapp
- Stephen R. DurhamSDStephen R. Durham
Open Access
- 1 February 2008
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 121 (2) , 512-518.e2
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Five‐year follow‐up on the PAT study: specific immunotherapy and long‐term prevention of asthma in childrenAllergy, 2006
- Prevalence and rate of diagnosis of allergic rhinitis in EuropeEuropean Respiratory Journal, 2004
- Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2004
- Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)Journal of Allergy and Clinical Immunology, 2002
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999
- Allergen immunotherapy: therapeutic vaccines for allergic diseasesAllergy, 1998
- Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?Clinical & Experimental Allergy, 1998
- Impact of upper respiratory allergic diseases on quality of lifeJournal of Allergy and Clinical Immunology, 1998
- Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up studyAllergy, 1995
- Does the effect of immunotherapy last after termination of treatment?Allergy, 1988